Trial Profile
A pivotal Clinical trial of Human retinal pigment epithelial cell therapy in patients with Stargardt's Macular Degeneration
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2017
Price :
$35
*
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
- Indications Stargardt disease
- Focus Therapeutic Use
- Sponsors Astellas Institute for Regenerative Medicine
- 19 Aug 2015 According to Ocata Therapeutics media release, company is planning to initiate this trial in the fourth quarter of this year.
- 24 Mar 2015 New trial record